Main menu


WuXi ATU Announces Licensing Agreement for TESSA™ Technology with Janssen

featured image

Philadelphia, August 11, 2022 /PRNewswire/ — WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”) Did. Under the agreement, WuXi ATU will license TESSA™ technology to Janssen, a high performance system capable of producing 10 times more adeno-associated virus (AAV) vectors than his traditional AAV manufacturing system. Janssen also has access to study WuXi ATU’s proprietary clonal suspension HEK293 cell line. The deal was facilitated by Johnson & Johnson Innovation.

AAV vectors are commonly used to deliver gene therapy to patients due to their ability to transduce many cell and tissue types. WuXi ATU’s TESSA™ technology meets industry demand for large-scale His AAV production by more efficiently producing high-quality His AAV particles. WuXi ATU also successfully scaled up TESSA™ technology to 200L. This resulted in 10-fold higher yields and significantly higher percentages of intact AAV capsids compared to the conventional plasmid-based His AAV production system, significantly reducing overall AAV production costs.

“We are honored that Janssen has chosen WuXi ATU’s TESSA™ technology,” said Dr. David Chang, CEO of WuXi Advanced Therapies. “We continue to work on improving the TESSA™ platform to produce faster, more cost-effective AAV products for patients.”

As a contract testing, development and manufacturing organization (CTDMO) with global operations, WuXi ATU is dedicated to helping our clients develop and deliver life-changing cell and gene therapies for patients in need more rapidly. We will continue to strengthen our capabilities and capabilities.

About WuXi Advanced Therapies (WuXi ATU)

WuXi Advanced Therapies, WuXi AppTec’s advanced therapeutics business unit, is a contract research, development and manufacturing organization (CTDMO) that provides an integrated platform to transform the discovery, development, testing, manufacturing and commercialization of cell and gene therapies. . Our services and solutions accelerate time to market and support customer programs around the world. For more information, please visit

About Wuxi Uptech

As a global company with operations all over the world Asia, EuropeWhen North AmericaWuXi AppTec offers a broad portfolio of R&D and manufacturing services, enabling the global pharmaceutical and healthcare industries to advance discoveries and deliver breakthrough therapies to patients. Through its unique business model, WuXi AppTec’s integrated end-to-end services include Chemical Pharmaceutical CRDMO (Contract Research, Development and Manufacturing Organization), Biological Discovery, Preclinical and Clinical Research Services, Cell and Gene Therapy Includes CTDMO (Contract Testing, Development and Manufacturing Organization). Helping customers improve productivity in advanced healthcare products through cost-effective and efficient solutions. WuXi AppTec will receive an AA ESG rating from MSCI in 2021, and its open access platform will enable over 5,850 collaborators from over 30 countries to improve health for those in need, empowering them to “make every medicine possible. We can realize the vision that we can prevent all diseases. It can be treated. Please visit:

Source Wuxi AppTec